Aclaris Therapeutics, Inc. (ACRS)
Company Info
| ISIN | US00461U1051 |
|---|---|
| CUSIP | 00461U105 |
| Sector | Healthcare |
| Industry | Biotechnology |
Highlights
| Market Cap | $100.13M |
|---|---|
| EPS (TTM) | -$1.09 |
| PEG Ratio | -0.13 |
| Total Revenue (TTM) | $29.25M |
| Gross Profit (TTM) | $20.13M |
| EBITDA (TTM) | -$88.13M |
| Year Range | $0.59 - $10.15 |
| Target Price | $1.84 |
| Short % | 6.60% |
| Short Ratio | 3.75 |
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Popular comparisons: ACRS vs. BFLY
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Aclaris Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Aclaris Therapeutics, Inc. had a return of 28.57% year-to-date (YTD) and -86.32% in the last 12 months.
| Period | Return | Benchmark |
|---|---|---|
| Year-To-Date | 28.57% | 13.20% |
| 1 month | 4.65% | -1.28% |
| 6 months | 8.00% | 10.32% |
| 1 year | -86.32% | 18.23% |
| 5 years (annualized) | -5.07% | 12.31% |
| 10 years (annualized) | N/A | 10.58% |
Monthly Returns
The table below presents the monthly returns of ACRS, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | 10.48% | 2.59% | 4.20% | -2.42% | -14.88% | 6.80% | 28.57% | ||||||
| 2023 | 7.30% | -26.27% | -35.07% | 9.89% | -6.07% | 24.19% | -4.82% | -24.21% | -8.42% | -27.30% | -82.44% | 20.04% | -93.33% |
| 2022 | -24.90% | 36.45% | 15.70% | -28.54% | 3.81% | 9.15% | 10.39% | 3.24% | -1.07% | -0.83% | -2.50% | 3.48% | 8.32% |
| 2021 | 220.71% | 7.37% | 13.11% | -5.36% | -6.75% | -21.04% | -14.98% | 8.57% | 11.04% | -3.61% | -26.22% | 13.59% | 124.73% |
| 2020 | -34.39% | -8.06% | -8.77% | 27.88% | 6.02% | 14.89% | 32.72% | 14.42% | 4.47% | 49.42% | -13.02% | 93.71% | 242.33% |
| 2019 | -5.68% | -7.03% | -7.56% | 5.18% | -25.71% | -53.21% | -41.55% | -21.09% | 6.93% | 62.04% | -6.29% | 15.24% | -74.42% |
| 2018 | -10.30% | -9.86% | -12.14% | 1.31% | 1.80% | 10.51% | -14.17% | -7.12% | -8.79% | -18.11% | -21.61% | -20.71% | -70.03% |
| 2017 | -2.25% | 17.72% | -4.51% | -5.73% | -15.40% | 14.05% | 6.19% | -9.97% | -0.46% | -2.32% | -5.95% | 4.01% | -9.14% |
| 2016 | -17.48% | -17.50% | 3.33% | -2.48% | 8.12% | -7.56% | 6.66% | 2.34% | 27.03% | -17.02% | 40.94% | -9.38% | 0.74% |
| 2015 | 30.95% | 62.75% | 14.39% | 143.80% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of ACRS is 15, indicating that it is in the bottom 15% of stocks on our website in terms of risk-adjusted performance. This ranking is based on the combined values of the indicators listed below.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Aclaris Therapeutics, Inc. (ACRS) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Aclaris Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Aclaris Therapeutics, Inc. was 98.05%, occurring on Nov 13, 2023. The portfolio has not yet recovered.
The current Aclaris Therapeutics, Inc. drawdown is 95.91%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -98.05% | Apr 18, 2017 | 1656 | Nov 13, 2023 | — | — | — |
| -49.56% | Dec 23, 2015 | 63 | Mar 24, 2016 | 173 | Nov 29, 2016 | 236 |
| -19.68% | Dec 19, 2016 | 34 | Feb 7, 2017 | 13 | Feb 27, 2017 | 47 |
| -13.11% | Nov 24, 2015 | 7 | Dec 3, 2015 | 9 | Dec 16, 2015 | 16 |
| -12.04% | Mar 7, 2017 | 11 | Mar 21, 2017 | 18 | Apr 17, 2017 | 29 |
Volatility
Volatility Chart
The current Aclaris Therapeutics, Inc. volatility is 19.18%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
P/E Ratio
The chart below displays the historical trend of the price-to-earnings (P/E) ratio for Aclaris Therapeutics, Inc..
Loading data...
Income Statement
| TTM | |
|---|---|
| Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
| Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
| Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |